Alternatives to MyBioSource
MyBioSource is a Biotechnology tool: global supplier of research reagents including antibodies, proteins, and ELISA kits. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotechnology companies to MyBioSource
- Website
Abcam61BiotechnologyCambridge, United Kingdom$256.9MGlobal supplier of life science research tools, including antibodies, reagents, and assays.
- Website THThermo Fisher Scientific78Life SciencesWaltham, United States$5.5B
Global leader in serving science, providing analytical instruments, consumables, and services for research, diagnostics, and manufacturing.
- Website BIBioLegendBiotechnologySan Diego, United States
Developer and manufacturer of antibodies and reagents for biomedical research.
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website
Mammoth Biosciences63BiotechnologyBrisbane, United States$460.0MBiotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.
- Website
Epicrispr Biotechnologies62BiotechnologySouth San Francisco, United States$90.0MEpicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
- Website
Vizgen61BiotechnologyWaltham, United States$169.5MSpatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.
- Website
LifeMine Therapeutics Inc.60BiotechnologyWatertown, United States$543.0MClinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
- Website
Quartzy60BiotechnologyHayward, USA$40.0MA vertically-integrated procurement platform for the life sciences industry.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
Freenome59BiotechnologySouth San Francisco, USA$570.0MFreenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website
Pixelgen Technologies62BiotechnologyStockholm, Sweden$43.5MA life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
- EAEarendil Labs56BiotechnologyBeijing, China$787.0M
Earendil Labs is an AI biotechnology company focused on leveraging artificial intelligence for drug discovery and development of next-generation biologics.
- Website SPSpliceBio54BiotechnologyCambridge, United States$100.0M
Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.
- Website
Transcripta Bio54BiotechnologyPalo Alto, United States$24.0MAI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.
- Website
Waypoint Bio53BiotechnologyNew York, USA$20.0MAI-native biotech company designing next-generation CAR T therapies for solid tumors.
- Website KHKhartis Therapeutics, Inc.53BiotechnologySan Diego, United States$50.0M
Developing oral small molecule medicines for immunological and chronic diseases.
- Website
Rejuvenate Bio52BiotechnologyCambridge, USA$6.0MDeveloping novel therapies to reverse aging and extend lifespan.
Showing the 20 closest matches. See the rest on the MyBioSource profile.
Compare MyBioSource head to head
Side by side on what each one does, what it costs, and what real users report.